drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody
drug_description
Monoclonal IgG1 antibody targeting B7-H3 (CD276) on tumor cells; engages NK cells via Fc to drive antibody-dependent cellular cytotoxicity (ADCC).
nci_thesaurus_concept_id
C97510
nci_thesaurus_preferred_term
Enoblituzumab
nci_thesaurus_definition
An Fc-domain optimized, humanized monoclonal antibody directed against cancer stem cells (CSCs), with potential immunomodulating and antineoplastic activities. After binding of enoblituzumab to an as of yet not elucidated target expressed on CSCs and differentiated tumor cells, this agent may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CSCs. CSCs are tumor initiating cells that are able to self-renew and are responsible for tumor cell growth and resistance.
drug_mesh_term
Enoblituzumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized, Fc‑engineered IgG1 monoclonal antibody targeting B7‑H3 (CD276) on tumor cells; binding flags tumor cells for immune elimination by engaging FcγRIIIa (CD16) on NK cells to drive potent antibody‑dependent cellular cytotoxicity (ADCC), with additional Fc‑mediated effector functions (e.g., macrophage engagement) possible. No payload; primary effect is target‑specific immune‑mediated cytotoxicity.
drug_name
Enoblituzumab
nct_id_drug_ref
NCT05708924